Outlook Therapeutics (OTLK)
NASDAQ:OTLK
Top Page
Outlook Therapeutics
(NASDAQ:OTLK)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.20
▼(-5.71% Downside)
Action:DowngradedDate:03/26/26
The score is driven down primarily by very weak financials (large ongoing losses, negative equity, and heavy cash burn) and bearish technicals (price below major moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend, while recent corporate events add further financing and listing-risk overhang despite some regulatory-engagement positives.
Positive Factors
Clinical efficacy & FDA engagement
NORSE TWO met primary and key secondary visual acuity endpoints and the company held a Type A meeting to align with the FDA on confirmatory data. Sustained regulatory dialogue around pivotal efficacy is a structural positive: resolving the FDA’s substantial-evidence questions could enable U.S. approval, materially improving commercialization prospects and long-term revenue visibility for an on-label bevacizumab alternative.
Negative Factors
Severe cash burn & negative equity
The company reports sharply lower revenue (TTM -85.46%), persistent operating losses and negative shareholders’ equity, with operating and free cash flow deeply negative across periods. This structural cash shortfall forces ongoing dependence on external financing, constrains R&D and commercialization spend, and elevates dilution or insolvency risk absent new funding over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy & FDA engagement
NORSE TWO met primary and key secondary visual acuity endpoints and the company held a Type A meeting to align with the FDA on confirmatory data. Sustained regulatory dialogue around pivotal efficacy is a structural positive: resolving the FDA’s substantial-evidence questions could enable U.S. approval, materially improving commercialization prospects and long-term revenue visibility for an on-label bevacizumab alternative.
Read all positive factors
Outlook Therapeutics (OTLK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$17.60M
Dividend YieldN/A
Average Volume (3M)1.37M
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue GrowthN/A
EPS Growth86.28%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding83,067,190
10 Day Avg. Volume1,651,125
30 Day Avg. Volume1,372,157
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)26.09
P/FCF Ratio>-0.01
Enterprise Value/Market Cap2.09
Enterprise Value/Revenue179.18
Enterprise Value/Gross Profit-30.44
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$2.50Price Target Upside1090.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$21.21M
Outlook Therapeutics Business Overview & Revenue Model
Company Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of b...
How the Company Makes Money
null...
Outlook Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in regulatory approvals and clinical trials, along with a strong financial position. However, there were delays in the BLA resubmission timeline and increased expenses. Overall, the positive developments and strategic advancements outweigh the challenges noted.Positive Updates
Regulatory Approvals in the EU and UK
Outlook Therapeutics received marketing authorization for an ophthalmic formulation of bevacizumab for the treatment of retina diseases in the European Union and the United Kingdom.
Negative Updates
Delay in BLA Resubmission
BLA resubmission with the FDA has been pushed to the first calendar quarter of 2025 due to enrollment timelines not being met as initially anticipated.
Read all updates
Q3-2024 Updates
Positive
Negative
Regulatory Approvals in the EU and UK
Outlook Therapeutics received marketing authorization for an ophthalmic formulation of bevacizumab for the treatment of retina diseases in the European Union and the United Kingdom.
Read all positive updates
Company Guidance
During the Q3 2024 earnings call, Outlook Therapeutics provided several key updates and guidance metrics. The company announced it has received marketing authorization for its ophthalmic formulation of bevacizumab in the European Union and the United Kingdom. They are preparing for commercial launch in these regions in the first half of 2025, with ongoing market access work and inventory planning. In the United States, the NORSE EIGHT clinical trial is progressing, with 359 of the planned 400 subjects enrolled, and completion expected by the end of Q3 2024. Outlook Therapeutics anticipates top-line results from NORSE EIGHT in Q4 2024 and plans to resubmit the Biologics License Application (BLA) to the FDA in Q1 2025. Financially, the company reported a reduction in adjusted net loss and R&D expenses from the previous quarter, with a cash position of $32 million as of June 30, 2024, and expected proceeds of $107 million from the exercise of warrants, supporting operations through 2025.Outlook Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 205.53K | 1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.21M | 657.21K | -113.86K | -44.19K | -204.69K | -262.14K |
| EBITDA | -60.47M | -63.58M | -72.09M | -57.38M | -64.36M | -51.51M |
| Net Income | -102.86M | -62.42M | -75.37M | -58.98M | -66.05M | -53.16M |
Balance Sheet | ||||||
| Total Assets | 18.24M | 18.58T | 28.82M | 32.30M | 28.53M | 22.81M |
| Cash, Cash Equivalents and Short-Term Investments | 8.68M | 8.08T | 14.93M | 23.39M | 17.40M | 14.48M |
| Total Debt | 36.89M | 247.70B | 29.74M | 35.56M | 10.96M | 11.90M |
| Total Liabilities | 56.79M | 50.77T | 101.90M | 46.74M | 19.79M | 18.20M |
| Stockholders Equity | -38.55T | -32.19T | -73.08M | -14.44M | 8.74M | 4.61M |
Cash Flow | ||||||
| Free Cash Flow | -14.94T | -51.83T | -68.79M | -42.97M | -56.67M | -54.25M |
| Operating Cash Flow | -14.94T | -51.83T | -68.79M | -42.97M | -56.67M | -54.25M |
| Investing Cash Flow | -3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 15.53T | 44.98T | 60.33M | 48.97M | 59.59M | 56.19M |
Outlook Therapeutics Technical Analysis
Negative
0.21
Price Trends
0.43
Negative
1.01
Negative
1.32
Negative
Market Momentum
-0.06
Positive
26.84
Positive
17.03
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLK, the sentiment is Negative. The current price of 0.21 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.43, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 26.84 is Positive, neither overbought nor oversold. The STOCH value of 17.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLK.
Outlook Therapeutics Risk Analysis
Outlook Therapeutics disclosed 75 risk factors in its most recent earnings report. Outlook Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Outlook Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $139.31M | 0.57 | 27.20% | ― | ― | 814.20% | |
53 Neutral | $191.82M | -1.36 | -63.41% | ― | -87.59% | 11.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $169.44M | -7.27 | -10.35% | ― | -42.62% | ― | |
44 Neutral | $34.89M | -0.59 | 763.31% | ― | -15.81% | -113.06% | |
42 Neutral | $40.56M | -16.66 | -79.12% | ― | 51.27% | ― | |
40 Underperform | $17.60M | -1.03 | <0.01% | ― | ― | 86.28% |
* Healthcare Sector Average
OTLK
Outlook Therapeutics
0.21
-1.19
-85.14%
ORMP
Oramed Pharm
3.50
1.36
63.25%
ATRA
Atara Biotherapeutics
4.96
-1.92
-27.91%
WHWK
Whitehawk Therapeutics
3.59
1.69
88.95%
CELU
Celularity
1.21
-0.67
-35.64%
ADAG
Adagene
4.07
2.41
145.18%
Outlook Therapeutics Corporate Events
Private Placements and Financing
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants
Negative
Mar 25, 2026
On March 23, 2026, Outlook Therapeutics, Inc. launched a best-efforts public offering of 20,000,000 shares of common stock bundled with warrants to purchase an equal number of shares at a combined price of $0.25, with H.C. Wainwright Co., LLC act...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Outlook Therapeutics Refinances Debt, Extends Note Maturities
Negative
Mar 16, 2026
On March 16, 2026, Outlook Therapeutics entered into a Note Purchase Agreement with Atlas Sciences for an unsecured promissory note with an original principal balance of $18.36 million, issued at a discount for $17 million in proceeds, which were ...
Executive/Board Changes
Outlook Therapeutics Announces Board Resignation and Size Reduction
Neutral
Mar 12, 2026
On March 6, 2026, Outlook Therapeutics’ board accepted the resignation of director Dr. Julia Haller, effective March 11, 2026, and voted to reduce the size of the board to nine members upon her departure. Dr. Haller, a Class II director and ...
Executive/Board ChangesShareholder Meetings
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
Positive
Mar 11, 2026
At its annual meeting held on March 10, 2026, Outlook Therapeutics shareholders elected three Class I directors — Yezan Haddadin, Faisal G. Sukhtian and Kurt J. Hilzinger — to serve on the board until the 2029 annual meeting, reinforci...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval
Positive
Mar 5, 2026
On March 5, 2026, Outlook Therapeutics reported it had held a Type A meeting with the U.S. Food and Drug Administration to address a December 30, 2025 complete response letter for its biologics license resubmission for ONS-5010/LYTENAVA™, an...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance
Negative
Feb 18, 2026
On February 18, 2026, Outlook Therapeutics received notice from Nasdaq that its common stock had closed below the required $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s continued listing...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA
Negative
Feb 11, 2026
On February 11, 2026, Outlook Therapeutics announced it had requested a Type A meeting with the U.S. Food and Drug Administration to address a Complete Response Letter dated December 30, 2025, relating to its resubmitted biologics license applicat...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
FDA Issues New Setback for Outlook Therapeutics’ LYTENAVA
Negative
Jan 2, 2026
On December 31, 2025, Outlook Therapeutics reported that the U.S. Food and Drug Administration issued a Complete Response Letter to its resubmitted biologics license application for ONS-5010/LYTENAVA for the treatment of wet age-related macular de...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.